Search Results for agency_names:"Health and Human Services Department"

The National Eye Institute announced a closed meeting of the National Advisory Eye Council, scheduled for April 21, 2025, from 10:00 a.m. to 1:00 p.m. This meeting is closed to the public because it involves reviewing grant applications and contract proposals that could reveal sensitive trade secrets and personal information. The meeting will be held virtually, and additional information can be found on the Institute's website. Dr. Kathleen C. Anderson is the contact person for the meeting.

The Centers for Disease Control and Prevention (CDC) has announced a closed meeting scheduled for March 19, 2025. This meeting, which will be conducted via teleconference, will focus on reviewing and evaluating grant applications related to the incidence of epilepsy among children in the United States. The meeting is closed to the public due to the discussion of confidential information such as trade secrets and personal information. Dr. Catherine Barrett is the contact person for further information regarding the meeting.

The National Institutes of Health (NIH) is offering a government-owned invention for licensing. This invention is a vaccine that uses a virus vector called VSV-EBOV to express the spike protein of the SARS-CoV-2 virus, which causes COVID-19. The vaccine has shown effective protection against the virus in animal tests, and it only requires a single dose. It is designed to be inexpensive to produce and provides high levels of antibodies to fight COVID-19.

The Food and Drug Administration (FDA) is removing its approval for eight different abbreviated new drug applications (ANDAs), as the companies that made these drugs informed the FDA that the drugs are no longer being sold. The companies asked the FDA to cancel these approvals, and the FDA has agreed to do so as of April 14, 2025. Even though approval is being withdrawn, the decision does not prevent the companies from filing new applications in the future if desired. Also, any existing drugs from the list that are still in stock after this date can be sold until they run out, expire, or otherwise become unsuitable.

The National Institute of Allergy and Infectious Diseases (NIAID) announced a closed meeting of their Special Emphasis Panel. The meeting, scheduled for April 30 to May 1, 2025, will review grant applications focused on strategies for eliminating HIV proteins. Because the discussions might involve confidential information or personal details, the meeting will not be open to the public. It will take place via video conference, and Stephen A. Gallo, Ph.D., will be the contact person for further inquiries.

The Food and Drug Administration (FDA) has proposed a collection of information regarding laboratory accreditation for food analysis and submitted it to the Office of Management and Budget (OMB) for review under the Paperwork Reduction Act. The accreditation program aims to ensure food safety by allowing laboratories accredited by recognized bodies to conduct food testing. This program is voluntary, and the FDA estimates a decrease in the number of respondents and burden hours compared to the previous collection data. The public can submit comments by January 21, 2025, through the specified online portal.

The Food and Drug Administration (FDA) has issued a priority review voucher to the sponsor of the rare pediatric disease product, CRENESSITY (crinecerfont). This voucher is awarded under the Federal Food, Drug, and Cosmetic Act, which allows such recognition for approved products meeting specific criteria. CRENESSITY is manufactured by Neurocrine Biosciences, Inc., and was approved on December 13, 2024, for the treatment of classic congenital adrenal hyperplasia in adults and children aged four and older. This announcement fulfills FDA's requirement to publish notice of such awards.

The Office of Planning, Research, and Evaluation (OPRE) within the Administration for Children and Families (ACF) is seeking public comments on new report templates for the Healthy Marriage and Responsible Fatherhood (HMRF) programs. These templates are intended to help grant recipients efficiently report their evaluation findings as required by the ACF. The request is connected to the HMRF Local Evaluation Technical Assistance projects, which support the evaluation of programs aimed at improving family stability and healthy relationships. Public comments must be submitted by January 6, 2025, to be considered in OMB’s decision-making process.

The Food and Drug Administration (FDA) has announced the renewal of its Science Board, extending its charter until June 26, 2026. This board provides expert advice to the FDA on various complex scientific and technical issues crucial to the agency's mission, including areas like food safety, pharmacology, and public health. The board consists of 21 voting members, with additional members or consultants temporarily added as necessary for specific expertise. The renewal confirms that it is in the public interest to maintain this advisory board for at least two more years.

The National Human Genome Research Institute has announced a change to their upcoming meeting schedule. Originally set to begin the open session at 10 a.m. on February 10, 2025, the start time has been pushed to 11:30 a.m. The meeting will still conclude on February 11, 2025, and it is partially open to the public. This amendment was officially noted in the Federal Register as part of the document with the number 2025-01327.